UCB Moves Up Myasthenia Gravis Pipeline With Rozanolixizumab Win
Slips Into Second Place Behind Argenx's Efgartigimod
Argenx's efgartigimod could very soon become the first anti-FcRn agent to get approval for generalized myasthenia gravis but UCB’s rival therapy rozanolixizumab for the rare muscular disease is nearly ready to be filed with regulators.
